AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1483671
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg in saline solution
Trial: 30473097
Drug: LY3298176 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3298176 10 mg
Trial: 30473097
Drug: LY3298176 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3298176 15 mg
Trial: 30473097
Drug: LY3298176 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3298176 1.5 mg
Trial: 30473097
Drug: LY3298176 4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3298176 4.5 mg
Trial: 27225316
Drug: n‐3 LCPUFA‐rich
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n‐3 LCPUFA‐rich fish oil capsules (800 mg/d DHA and 100 mg/d EPA)
Trial: 24316517
Drug: Vancomycin 500
RxNorm normalized name: vancomycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin 500 mg t.i.d. for 7 days
Trial: 24316517
Drug: Amoxicillin 500
RxNorm normalized name: amoxicillin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 500 mg t.i.d. for 7 days
Trial: 23880333
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) group
Trial: 22356596
Drug: Supportive-experiential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive-experiential therapy (SET) group
Trial: 20504210
Drug: Rasagiline monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rasagiline monotherapy
Trial: 20504210
Drug: Rasagiline therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rasagiline therapy
Trial: 18561718
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of ciprofloxacin given 24 hours before return
Trial: 15991508
Drug: Dexmedetomidine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine + 3 mg kg(‐1) lidocaine
Trial: 15991508
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (3 mg kg(‐1) lidocaine diluted with saline)
Trial: 6541533
Drug: High-dose dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dexamethasone (DXM) (regimen A)
Trial: 6541533
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of DXM and high doses of metoclopramide (MCP) (regimen B)
Trial: 27694568
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg iron and 400 μg folic acid
Trial: 23867040
Drug: Functional electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Functional electrical stimulation with mirror therapy (FES with MT)
Trial: 23867040
Drug: Functional electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Functional electrical stimulation without mirror therapy (FES without MT)
Trial: 22314470
Drug: Oral nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral nifedipine (n=50)
Trial: 3529351
Drug: Sequential female
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential female sex hormones and/or 1,25(OH)2D3, 0.25 microgram per day
Trial: 29352461
Drug: Probiotic L.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic L. reuteri lozenge (1 lozenge daily for 30 days)
Trial: 29352461
Drug: Mechanical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical therapy alone (Control)
Trial: 29352461
Drug: Probiotic L.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic L. reuteri lozenge
Trial: 18536619
Drug: Hib‐MenC‐TT booster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hib‐MenC‐TT booster dose
Trial: 15452683
Drug: Diazepam (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (15 mg/70 kg)
Trial: 15452683
Drug: Flumazenil (1
RxNorm normalized name: Flumazenil (18-F)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (1 mg/70 kg, intravenously administered)
Trial: 10064355
Drug: Creatine phosphate-enriched
RxNorm normalized name: Creatine phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine phosphate-enriched cardioplegic solution (group I)
Trial: 10064355
Drug: Standard cardioplegic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard cardioplegic solution (group II)
Trial: 1838923
Drug: perindopril (ACE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: perindopril (ACE inhibitor)
Trial: 25768849
Drug: Istradefylline 20
RxNorm normalized name: istradefylline 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Istradefylline 20 mg/d (with possible adjustment to 40 mg/d)
Trial: 25768849
Drug: Istradefylline 20
RxNorm normalized name: istradefylline 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Istradefylline 20 mg/d and 40 mg/d (previously taken in double-blind study)
Trial: 19478653
Drug: Intramuscular oxygen-ozone
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular oxygen-ozone (O2O3) therapy
Trial: 3307889
Drug: Simulated therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simulated therapy (control)
Trial: 16048250
Drug: Low glucose
RxNorm normalized name: ONE TOUCH LOW GLUCOSE CONTROL SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low glucose degradation product (GDP) dialysis solution
Trial: 10073749
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg single dose)
Trial: 10073749
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg daily for at least 1 week)
Trial: 2043179
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of quinine sulfate plus theophylline ethylene diamine (CTED)
Trial: 6756775
Drug: Laminaria and
RxNorm normalized name: Laminaria digitata preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laminaria and continuous intravenous oxytocin infusion (Group C, 62 patients)
Trial: 27784409
Drug: cb‐CBT‐I (computer-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cb‐CBT‐I (computer-based cognitive behavioral therapy for insomnia)
Trial: 23614819
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine injection
Trial: 17922738
Drug: Calcitriol therapy
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcitriol therapy for 12 weeks
Trial: 14994363
Drug: Warming therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warming therapy (heating vest set to medium heat for 3 hours a day for 21 days)
Trial: 11679149
Drug: HIV-1 MN
RxNorm normalized name: Mn 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV-1 MN rgp160 ImmunoAG vaccine
Trial: 11679149
Drug: Highly active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highly active antiretroviral therapy (HAART) (ritonavir, didanosine, and stavudine)
Trial: 7524592
Drug: aprotinin (total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aprotinin (total dose 2,000,000 kallikrein inhibiting units)
Trial: 2908755
Drug: Balsalazide (BSZ)
DrugBank: Balsalazide (DB01014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Balsalazide (BSZ) 1 g b.d. orally
Trial: 2908755
Drug: Sulphasalazine (SASP)
RxNorm normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulphasalazine (SASP) 1 g b.d. orally
Trial: 28460409
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg TA
Trial: 28460409
Drug: 15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg TA
Trial: 22968854
Drug: 375 mg
RxNorm normalized name: niacin 375 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 375 mg fosphenytoin sodium
Trial: 22968854
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg phenytoin sodium
Trial: 22968854
Drug: Fosphenytoin sodium
RxNorm normalized name: Fosphenytoin Sodium
DrugBank: Fosphenytoin (DB01320)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fosphenytoin sodium (375, 563, and 750 mg)
Trial: 10355071
Drug: Intravenous enalaprilat
RxNorm normalized name: Enalaprilat
DrugBank: Enalaprilat (DB09477)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous enalaprilat (initial dose: 2.5 mg; repetitive application of 2.5 mg every 30 min until a cumulative dose of 10 mg)
Trial: 10355071
Drug: Sublingual nitroglycerine
RxNorm normalized name: nitroglycerin Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual nitroglycerine (initial dose: 0.8 mg; repetitive application of 0.8 mg every 10 min until a cumulative dose of 3.2 mg)
Trial: 1790550
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of oral ubidecarenone daily
Trial: 7214795
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (BDP) 2 mg/day
Trial: 7214795
Drug: Fluocortinbutyl (FCB)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluocortinbutyl (FCB) 40 mg/day
Trial: 18250184
Drug: M vaccae
RxNorm normalized name: Mycobacterium vaccae
DrugBank: Mycobacterium vaccae (DB18449)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M vaccae immunotherapy
Trial: 12824212
Drug: Diluted smallpox
RxNorm normalized name: Smallpox vaccine
DrugBank: Smallpox (Vaccinia) Vaccine, Live (DB14711)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diluted smallpox vaccine (1:3.2)
Trial: 12824212
Drug: Diluted smallpox
RxNorm normalized name: Smallpox vaccine
DrugBank: Smallpox (Vaccinia) Vaccine, Live (DB14711)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diluted smallpox vaccine (1:10)
Trial: 12824212
Drug: Diluted smallpox
RxNorm normalized name: Smallpox vaccine
DrugBank: Smallpox (Vaccinia) Vaccine, Live (DB14711)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diluted smallpox vaccine (1:32)
Trial: 12824212
Drug: Vaccinia‐naive participants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccinia‐naive participants (undiluted vaccine)
Trial: 1582788
Drug: Topical carteolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical carteolol 1%
Trial: 4015065
Drug: apalcillin 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: apalcillin 75 mg/kg
Trial: 4015065
Drug: apalcillin 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: apalcillin 150 mg/kg
Trial: 4015065
Drug: apalcillin 225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: apalcillin 225 mg/kg
Trial: 4015065
Drug: apalcillin (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: apalcillin (all doses)
Trial: 26825021
Drug: 20-30 mg/24h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-30 mg/24h morphine SR
Trial: 1441866
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml bupivacaine 0.125% with 12.5 micrograms epinephrine (test dose)
Trial: 1441866
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml normal physiologic saline (control)
Trial: 18459121
Drug: Group therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group therapy with hypnosis (and psychoeducation)
Trial: 23417664
Drug: Multidimensional Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidimensional Treatment Foster Care (MTFC)
Trial: 12507634
Drug: Lutein (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutein (15 mg, n = 5)
Trial: 12507634
Drug: Alpha-tocopherol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-tocopherol (100 mg, n = 6)
Trial: 1497931
Drug: Lidoflazine 1
RxNorm normalized name: lidoflazine 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidoflazine 1 mg/kg intravenously over a period of 20 min before initiation of cardiopulmonary bypass
Trial: 30596265
Drug: Expert moderated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expert moderated vaccine social media (VSM) website
Trial: 30596265
Drug: Publicly available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Publicly available parenting and vaccine-focused blogs and discussion forums
Trial: 25952586
Drug: Traditional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional therapy group (N=23)
Trial: 11952579
Drug: Glyceryl trinitrate
RxNorm normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glyceryl trinitrate (GTN) ointment (0.2%)
Trial: 11952579
Drug: Diltiazem hydrochloride
RxNorm normalized name: Diltiazem Hydrochloride
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diltiazem hydrochloride (DTZ) cream (2%)
Trial: 9458470
Drug: SPf66 (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPf66 (0.5 mg or 1.0 mg)
Trial: 9458470
Drug: SPf66 (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPf66 (high dose Colombian vaccine)
Trial: 3127188
Drug: Phenytoin sodium
RxNorm normalized name: Phenytoin Sodium
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenytoin sodium capsules 400 mg with enteral feedings (Ensure) at 100 ml/h for ten hours
Trial: 3127188
Drug: Phenytoin sodium
RxNorm normalized name: Phenytoin Sodium
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenytoin sodium capsules 400 mg without enteral feedings
Trial: 11564991
Drug: Valsartan 80
RxNorm normalized name: valsartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 80 mg o.d. (or valsartan 80 mg + HCTZ 12.5 mg o.d. after 4 weeks if needed)
Trial: 11564991
Drug: Amlodipine 5
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 mg o.d. (or amlodipine 10 mg o.d. after 4 weeks if needed)
Trial: 29474934
Drug: 1-dose regimen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1-dose regimen of HPV vaccine
Trial: 29474934
Drug: 2-dose regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-dose regimen of HPV vaccine
Trial: 24641624
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil supplementation (8 g day(-1) containing 1.6 g day(-1) eicosapentaenoic acid + docosahexaenoic acid)
Trial: 24641624
Drug: High oleic
RxNorm normalized name: High Oleic Sunflower Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High oleic sunflower oil (8 g day(-1))
Trial: 22160145
Drug: Darunavir/ritonavir monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darunavir/ritonavir monotherapy
Trial: 20802297
Drug: Darunavir/ritonavir triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darunavir/ritonavir triple drug regimen
Trial: 16782174
Drug: IL6 polymorphisms
RxNorm normalized name: IL6
DrugBank: Human interleukin-6 (DB15060)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL6 polymorphisms (specifically the -572 G>C polymorphism)
Trial: 15157691
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (10 sessions over 3-4 weeks at anti-pain acupoints)
Trial: 15157691
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (10 sessions over 3-4 weeks at placebo-points)
Trial: 9442782
Drug: Latanoprost (0.005%)
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Latanoprost (0.005%) administered once daily for 6 months
Trial: 9442782
Drug: Timolol (0.5%)
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Timolol (0.5%) administered twice daily for 6 months
Trial: 9442782
Drug: Latanoprost (0.005%)
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Latanoprost (0.005%) administered once daily for 18 months
Trial: 9442782
Drug: Latanoprost (0.005%)
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Latanoprost (0.005%) administered once daily for 24 months
Trial: 7992902
Drug: Esmolol 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol 0.75 mg/kg
Trial: 2729906
Drug: Pipram (pipemidic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pipram (pipemidic acid) 200 mg daily at bedtime for 6 months
Trial: 5100498
Drug: Gradual introduction
RxNorm normalized name: INTRODUCTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gradual introduction of treatment with levodopa
Trial: 5100498
Drug: Rapid introduction
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid introduction of treatment with levodopa
Trial: 5100498
Drug: Rate of
RxNorm normalized name: Citrate of Magnesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rate of increasing the dose of levodopa
Trial: 10899382
Drug: Mecamylamine 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mecamylamine 20 mg
Trial: 21644059
Drug: Scopolamine 0.5
RxNorm normalized name: scopolamine 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine 0.5 mg
Trial: 27858074
Drug: Implant anchorage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant anchorage
Trial: 21496949
Drug: Sevelamer hydrochloride
RxNorm normalized name: Sevelamer Hydrochloride
DrugBank: Sevelamer (DB00658)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevelamer hydrochloride (800 mg by mouth three times daily)
Trial: 18779378
Drug: Cinaciguat (50-250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinaciguat (50-250 microg/h) administered intravenously for up to 4 hours
Trial: 18779378
Drug: Cinaciguat (150-250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinaciguat (150-250 microg/h) administered intravenously for up to 4 hours
Trial: 11099083
Drug: 1-day intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-day intramuscular ceftriaxone (50 mg/kg)
Trial: 11099083
Drug: 3-day intramuscular
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-day intramuscular ceftriaxone (50 mg/kg/day)
Trial: 9495995
Drug: Psychological suggestion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychological suggestion therapy
Trial: 8394842
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (Seleparina, CY 216) administered as 2 x 3,825 anti‐Xa international units subcutaneously on the day of surgery followed by a single daily 3,825 anti‐Xa international units injection for 7 days.
Trial: 8394842
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (Seleparina, CY 216).
Trial: 2941473
Drug: Tricyclic antidepressants
RxNorm normalized name: TRICYCLIC ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tricyclic antidepressants (active medication)
Trial: 26880010
Drug: Conventional NAM
RxNorm normalized name: Ling Nam Ultra Balm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional NAM treatment (Group 1, n = 6)
Trial: 20483885
Drug: Memantine 10
RxNorm normalized name: Memantine 10mg Oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine 10 mg twice a day (4 week titration followed by 12 weeks on the highest tolerated dose)
Trial: 2404841
Drug: Doxorubicin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (20 mg/m2 day 1 and 8) in combination with PCOP regimen (cyclophosphamide 400 mg/m2 day 1 and 8, vincristine 1.4 mg/m2 day 1 and 8, procarbazine 80 mg/m2 day 1 to 14, prednisone 60 mg/m2 day 1 to 5)
Trial: 2404841
Drug: Doxorubicin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (20 mg/m2 day 1 and 8)
Trial: 6776543
Drug: Mazindol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mazindol (2 mg or occasionally 4 mg/day)
Trial: 31488360
Drug: Lomustine-temozolomide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lomustine-temozolomide (100 mg/m2 on day 1 plus 100-200 mg/m2 on days 2-6 for six 6-week courses)
Trial: 31488360
Drug: Temozolomide (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temozolomide (75 mg/m2 daily during radiotherapy plus six 4-week courses of temozolomide [150-200 mg/m2] on days 1-5)
Trial: 18302810
Drug: Nabilone 0.5
RxNorm normalized name: nabilone 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabilone 0.5 mg
Trial: 21461891
Drug: Brivanib alaninate
RxNorm normalized name: Brivanib alaninate
DrugBank: Brivanib alaninate (DB11865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivanib alaninate (800 mg) in fasting state
Trial: 21461891
Drug: Brivanib alaninate
RxNorm normalized name: Brivanib alaninate
DrugBank: Brivanib alaninate (DB11865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivanib alaninate (800 mg) following ingestion of a high-fat meal
Trial: 21461891
Drug: Brivanib alaninate
RxNorm normalized name: Brivanib alaninate
DrugBank: Brivanib alaninate (DB11865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivanib alaninate (800 mg) once daily until discontinuation (multiple doses)